Ubachs J, Ziemons J, Minis-Rutten IJG, Kruitwagen RFPM, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10:1165–74.

Article  PubMed  PubMed Central  Google Scholar 

Shih I-M, Wang Y, Wang T-L. The origin of ovarian Cancer species and precancerous landscape. Am J Pathol. 2021;191:26–39.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pavlidis N, Rassy E, Vermorken JB, Assi T, Kattan J, Boussios S, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045.

Article  PubMed  Google Scholar 

Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2018;88:31–7.

Article  PubMed  CAS  Google Scholar 

Teng Z, Han R, Huang X, Zhou J, Yang J, Luo P et al. Increase of Incidence and Mortality of Ovarian Cancer during 2003–2012 in Jiangsu Province, China. Front Public Health [Internet]. 2016 [cited 2024 Nov 5];4. Available from: https://www.frontiersin.org/journals/public-health/articles/https://doi.org/10.3389/fpubh.2016.00146/full

Wang Y, Wu X, Ren Z, Li Y, Zou W, Chen J, et al. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist Updat. 2023;66:100916.

Article  PubMed  CAS  Google Scholar 

Wang S, Liu S, Liu F, Guo Y, Han F. Does A high peritoneal cancer index lead to A worse prognosis of patients with advanced ovarian cancer? A systematic review and meta-analysis based on the latest evidence. Front Oncol. 2024;14:1421828.

Article  PubMed  PubMed Central  Google Scholar 

Zahra MA, Al-Taher A, Alquhaidan M, Hussain T, Ismail I, Raya I, et al. The synergy of artificial intelligence and personalized medicine for the enhanced diagnosis, treatment, and prevention of disease. Drug Metab Pers Ther. 2024;39:47–58.

Article  PubMed  CAS  Google Scholar 

Gumusoglu E, Gunel T, Gumusoglu E, Gunel T. The Role of Circulating Biomarkers in the Early Diagnosis of Ovarian Cancer. Ovarian Cancer - From Pathogenesis to Treatment [Internet]. IntechOpen; 2018 [cited 2024 Nov 5]. Available from: https://www.intechopen.com/chapters/60255

Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med. 2023;21:118.

Article  PubMed  PubMed Central  Google Scholar 

Sufyan M, Shokat Z, Ashfaq UA. Artificial intelligence in cancer diagnosis and therapy: current status and future perspective. Comput Biol Med. 2023;165:107356.

Article  PubMed  Google Scholar 

Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2022;39:120.

Article  PubMed  PubMed Central  Google Scholar 

Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, et al. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv. 2023;9:eadf7195.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, Nowis D. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. Front Mol Biosci. 2022;9:1073797.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J. 2020;18:2300–11.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-Generation Sequencing Technology: Curr Trends Advancements Biology (Basel). 2023;12:997.

CAS  Google Scholar 

Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, et al. The emerging roles of NGS in clinical oncology and personalized medicine. Pathol Res Pract. 2022;230:153760.

Article  PubMed  CAS  Google Scholar 

Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. Cancer Lett. 2020;471:61–71.

Article  PubMed  CAS  Google Scholar 

Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: catching the silent killer before it strikes. World J Clin Oncol. 2020;11:868.

Article  PubMed  PubMed Central  Google Scholar 

Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: A comprehensive review. Cancers. 2020;12:3730.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022;2:CD007929.

PubMed  Google Scholar 

Montagnana M, Benati M, Danese E. Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective. Ann Transl Med. 2017;5:276.

Article  PubMed  PubMed Central  Google Scholar 

Wu L, Shang W, Zhao H, Rong G, Zhang Y, Xu T, et al. In Silico screening of Circulating MicroRNAs as potential biomarkers for the diagnosis of ovarian Cancer. Dis Markers. 2019;2019:7541857.

Article  PubMed  PubMed Central  Google Scholar 

Ren A. Individualizing Ovarian Cancer Surveillance: Discovery and Validation of Serological Personalized Biomarkers of Recurrence Using Multiplex Proteomics Technologies [Internet] [Thesis]. 2021 [cited 2024 Nov 5]. Available from: https://tspace.library.utoronto.ca/handle/1807/109285

Barr CE, Funston G, Jeevan D, Sundar S, Mounce LTA, Crosbie EJ. The performance of HE4 alone and in combination with CA125 for the detection of ovarian Cancer in an enriched primary care population. Cancers (Basel). 2022;14:2124.

Article  PubMed  CAS  Google Scholar 

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12:28.

Article  PubMed  PubMed Central  Google Scholar 

Braicu EI, Krause CL, Torsten U, Mecke H, Richter R, Hellmeyer L, et al. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients. BMC Cancer. 2022;22:831.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010;11:111–6.

PubMed  Google Scholar 

Ibrahim M, Bahaa A, Ibrahim A, El Hakem AA, Abo-El Noor A, El Tohamy U. Evaluation of serum mesothelin in malignant and benign ovarian masses. Arch Gynecol Obstet. 2014;290:107–13.

PubMed  CAS  Google Scholar 

Mishra M, Ahmed R, Das DK, Pramanik DD, Dash SK, Pramanik A. Recent advancements in the application of Circulating tumor DNA as biomarkers for early detection of cancers. ACS Biomater Sci Eng. 2024;10:4740–56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mitchell S, Nikolopoulos M, El-Zarka A, Al-Karawi D, Al-Zaidi S, Ghai A, et al. Artificial intelligence in ultrasound diagnoses of ovarian cancer: A systematic review and Meta-Analysis. Cancers (Basel). 2024;16:422.

Article  PubMed  PubMed Central  Google Scholar 

Garg P, Mohanty A, Ramisetty S, Kulkarni P, Horne D, Pisick E, et al. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim Biophys Acta Rev Cancer. 2023;1878:189026.

Article  PubMed  CAS  Google Scholar 

van Nagell JR, Hoff JT. Transvaginal ultrasonography in ovarian cancer screening: current perspectives. Int J Womens Health. 2013;6:25–33.

Article  PubMed